About Pyxis Oncology Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://pyxisoncology.com/
Frequently Asked Questions
What is the 52-week range for PYXS?
The 52-week high is $5.55 and the 52-week low is $1.03.
What is the P/E ratio for PYXS?
The P/E ratio data is currently unavailable.
What is the dividend yield for PYXS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -101.77%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.34.
Analyst Recommendation Trends
Wall Street analyst consensus for PYXS over the last few months:
Latest PYXS News
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Which stocks are gapping on Wednesday?
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of their
Wednesday's pre-market session: top gainers and losers
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of
Pyxis Oncology stock falls on public offering announcement
Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) shares dropped 3.5% in after-hours trading Tuesday after the company announced a registered public offering of common stock and warrants.
Pyxis Oncology Announces Proposed Public Offering
BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stoc
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
PYXIS ONCOLOGY, INC.Common StockThis Supplement No. 1 to Prospectus Supplement (this "Supplement") supplements and amends the Prospectus Supplement dated November 26, 2025 (the "Prospectus Supplement").
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery
Pyxis Oncology receives a "Sell" rating due to high risk, an unproven pipeline, and looming cash constraints. Click here to read more on PYXS.
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma - Slideshow
2026-09-10. The following slide deck was published by Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma September 9, 2026 7:30 AM EDTCompany...
Pyxis Oncology shares fall 7% despite updated MICVO trial results
Pyxis Oncology (NASDAQ:PYXS) shares fell 7% on Tuesday after the biotechnology company released updated Phase 1 data for Micvotabart Pelidotin, or MICVO, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Among 33 efficacy-evaluable patients receiving MICVO at 5.
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19
Wells Fargo analyst Derek Archila maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $12 to $19.
Top movers in Wednesday's pre-market session
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups No new safety signals observed; tolerability profile expecte
Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.
Wondering what's happening in today's after-hours session?
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Event to be webcast live on September 9, 2026 at 7:30 a.m. ETBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) rec
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.
Pyxis Oncology To Present Updated Phase 1 MICVO Data In Head And Neck Cancer On A Live Webcast On September 9, 2026 At 7:30 a.m. ET
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m.
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, ef
Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-04 | Civik Thomas | +2,503,050 | - | - |
| 2026-08-20 | Dupont Jakob | +46,000 | - | - |
| 2026-08-12 | Civik Thomas | +250,956 | - | - |
| 2026-06-30 | Dupont Jakob | -35,000 | - | - |
| 2026-06-30 | Dupont Jakob | -35,000 | $3.06 | $107,100 |
| 2026-06-30 | Dupont Jakob | +35,000 | $1.6 | $56,000 |
| 2026-03-24 | Wadhane Jitendra | +262,635 | - | - |
| 2026-03-24 | Wadhane Jitendra | +109,461 | - | - |
| 2026-03-24 | Palani Santhosh | +45,867 | - | - |
| 2026-03-24 | Cline Darren S | +45,867 | - | - |
| 2026-03-24 | HUMPHREY RACHEL | +45,867 | - | - |
| 2026-03-24 | Dupont Jakob | +45,867 | - | - |
| 2026-03-24 | Metzger Michael A | +45,867 | - | - |
| 2026-03-24 | Lewis-Hall Freda C | +45,867 | - | - |
| 2026-03-24 | FLAVIN JOHN L | +45,867 | - | - |
| 2026-02-03 | Civik Thomas | +690,131 | - | - |